×

Biotech and Pharmaceuticals Medicine

  • *Q4 core EPS $1.21 vs consensus forecast $1.13. LONDON, Feb 2- AstraZeneca warned on Thursday that profit and revenue would both fall this year as cheap generic versions of its cholesterol drug Crestor continue to hit sales. Chief Executive Pascal Soriot reaffirmed his confidence in the trial, despite recent mixed developments in the hotly contested cancer...

  • ZURICH, Feb 1- Roche is looking to expand its $2 billion- per-year diabetes business, not sell it or spin it off. Sales of Roche's diabetes products in 2016 slipped 4 percent to 2 billion Swiss francs, hurt by price pressure in the United States and extending a slide that began in 2015.. One bright spot for the business was Asia, where a 16 percent sales rise was primarily...

  • We will continue to invest in the US regardless of Trump: Roche CEO

    Roche CEO Severin Schwan discusses his strategy in the U.S. despite President Donald Trump's protectionism, as well as pricing pressures around the world.

  • Merck CEO: We had a great conversation with Trump

    Following the meeting between President Donald Trump and leaders in the pharmaceutical industry, Merck CEO Ken Frazier and other CEOs talk about their discussions.

  • Trump: I'll oppose anything that hurts competition for smaller players

    President Donald Trump meets with leaders in the pharmaceutical industry.

  • U.S. President Donald Trump speaks before signing an executive order while surrounded by small business leaders in the Oval Office of the White House in Washington, D.C., U.S., on Monday, Jan. 30, 2017.

    President Donald Trump meets with leaders in the pharmaceutical industry.

  • Similar price rises for old drugs have sparked outrage in the United States, where former hedge fund manager Martin Shkreli was pilloried in 2015 for increasing the cost of an anti-parasitic medicine by more than 5,000 percent. The new analysis by British academics suggests Europe is not immune to such unexplained cost increases, although absolute prices...

  • Jan 26- Bristol-Myers Squibb Co on Thursday posted a fourth-quarter profit that fell short of Wall Street estimates and lowered its 2017 earnings forecast, citing tempered expectations for its key Opdivo immuno-oncology drug. For full-year 2017, the U.S. drugmaker cut its adjusted earnings per share outlook by 15 cents, to between $2.70 and $2.90.

  • Jan 26- Bristol-Myers Squibb Co on Thursday posted a fourth-quarter profit that fell short of Wall Street estimates and lowered its 2017 earnings forecast amid tempered expectations for its key Opdivo immuno-oncology drug. For full-year 2017, the U.S. drugmaker cut its adjusted earnings per share outlook by 15 cents to between $2.70 and $2.90.

  • Jan 26- Bristol-Myers Squibb Co on Thursday posted fourth-quarter profits that fell short of Wall Street estimates and lowered its 2017 earnings forecast amid tempered expectations for its key Opdivo immuno-oncology drug. For full-year 2017, the U.S. drugmaker said it now expects adjusted earnings of $2.70 to $2.90 per share, down from its previous range of...

  • Jan 26- Bristol-Myers Squibb Co on Thursday reported fourth-quarter profit that fell short of Wall Street estimates and lowered its 2017 earnings forecast amid tempered expectations for its key Opdivo immuno-oncology drug. For full-year 2017, the U.S. drugmaker said it now expects adjusted earnings of $2.70 to $2.90 per share, down from its previous range...

  • *China's drug reimbursement list last updated in 2009. SHANGHAI, Jan 26- China is set to add more than 300 new and traditional drugs to its list of medicines the state will help patients pay for, the first change in more than seven years that will boost treatments for cancer, kidney disease, hepatitis and haemophilia. Poor access to targeted cancer drugs is a...

  • ZURICH, Jan 25- The Novartis copy of Amgen's blockbuster psoriasis drug Enbrel will not go on sale before 2018 at the earliest because of the U.S. company's patent protection challenge, the Swiss drugmaker's head of generics told Reuters. Though the U.S. Food and Drug Administration has approved the biosimilar copy of Enbrel, called Erelzi, for rheumatoid...

  • Top investment trends that will grow regardless of GDP

    Alex Gunz, fund manager at Heptagon-Capital, discusses the top trends for investors to look out for in 2017.

  • Helium seeing reduced number of suppliers

    Thomas Abraham-James, CEO of Helium One, discusses the global helium market as well as new applications of the resource.

  • Uncertainty on drug prices a challenge for the sector: Pro

    Barbara Ryan, Barbara Ryan Advisors partner, discusses political rhetoric on drug pricing and how it may affect the biotech and pharmaceutical sectors.

  • Jan 19- The U.S. Food and Drug Administration said on Thursday it had approved Synergy Pharmaceuticals Inc's drug to treat chronic idiopathic constipation. However, the safety and effectiveness of the drug have not been established in patients less than 18 years of age, the FDA said. The company's shares were marginally down at $6.40 in extended trading.

  • Jan 24- Johnson& Johnson reported a smaller-than-expected rise in fourth-quarter sales, hurt by slowing demand for its pharmaceutical products and a strong dollar, and said it was looking at strategic options for its diabetes care division. J&J is seeking strategic options for its diabetes care division, specifically LifeScan Inc, Animas Corp and Calibra...

  • PhRMA CEO: Need to focus on value of drugs, not prices

    Stephen Ubl, Pharmaceutical Research and Manufacturers of America (PhRMA) president & CEO, discusses the political rhetoric around the pharma industry and drug pricing.

  • *JPMorgan downgraded Indonesia at time of uncertainty- finmin. *Indonesia says bond dealers must avoid conflicts of interest. JPMorgan published a research report on Nov. 13 that gave Indonesia an underweight assessment, just as Southeast Asia's biggest economy was seeing an outflow of funds along with other emerging markets after Donald Trump's victory in...